Dermata Therapeutics Inc. (DRMA) Financial Statements (2024 and earlier)

Company Profile

Business Address 3525 DEL MAR HEIGHTS RD., #322
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments  6,24110,799
Cash and cash equivalents  6,24110,799
Other undisclosed current assets   825
Total current assets:  6,24111,624
Noncurrent Assets
Other undisclosed assets7,979703 
TOTAL ASSETS:7,9796,94411,624
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8669231,517
Accounts payable866497515
Accrued liabilities  4261,002
Total current liabilities:8669231,517
Noncurrent Liabilities
Other undisclosed liabilities758  
Total liabilities:1,6249231,517
Equity
Equity, attributable to parent6,3556,02210,107
Common stock011
Additional paid in capital59,74351,61446,089
Accumulated deficit(53,388)(45,593)(35,982)
Total equity:6,3556,02210,107
TOTAL LIABILITIES AND EQUITY:7,9796,94411,624

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Revenues
(Contractually Specified Servicing Fee, Late Fee, and Ancillary Fee Earned in Exchange for Servicing Financial Asset)
   
Gross profit:   
Operating expenses(8,042)(9,674)(7,857)
Other undisclosed operating loss   
Operating loss:(8,042)(9,674)(7,857)
Interest and debt expense   (46)
Loss from continuing operations:(8,042)(9,674)(7,902)
Loss before gain (loss) on sale of properties:(7,902)
Other undisclosed net income   
Net loss:(8,042)(9,674)(7,902)
Other undisclosed net income (loss) attributable to parent24764 
Net loss attributable to parent:(7,795)(9,611)(7,902)
Preferred stock dividends and other adjustments   (2,293)
Other undisclosed net loss available to common stockholders, basic   (269)
Net loss available to common stockholders, diluted:(7,795)(9,611)(10,465)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(8,042)(9,674)(7,902)
Comprehensive loss, net of tax, attributable to parent:(8,042)(9,674)(7,902)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: